Global Varicella Attenuated Live Vaccine Market Analysis 2020 with Top Companies, Production, Consumption,Price and Growth Rate By Innovation Market Research, Inc

 Pulichser: XYZResearch

February 2020

 Pages: 107

 IMR 1150

The Global consumption of varicella attenuated live vaccine products rises up from 34.99million doses in 2012 to 39.81 million doses in 2016, with an average annual growth rate of 3.44 %. At the same time, the revenue of world varicella attenuated live vaccine market has a leap from 1154.37 million dollars to 1515.52 million dollars. The reason causes this increase is the growing demand for the varicella attenuated live vaccine products, which is the outcome of the downstream industries are in a good situation.

A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.

The downstream industries of varicella attenuated live vaccine products are kids and adults. In the recent years, with the recovery of global economic, the development of emerging countries and the rising health concern, the consumption increase of varicella attenuated live vaccine will be obvious. In the foreseeable future, the varicella attenuated live vaccine products will show an optimistic upward trend.

As for the global varicella attenuated live vaccine industry, the industry structure is relatively concentrated. 60.07% of market share in sales was grasped by Merck and GSK. The United States giant Merck, which had 48.70% market share in 2016, was the leader in the varicella attenuated live vaccine industry. The manufacturers following Merck are GSK and BCHT, which respectively had 11.3% and 10.8% market share globally. The BCHT was the leader of China varicella attenuated live vaccine industry. It sold a total of 76.26 million dollars in the year of 2016.

The classification of consumption of varicella attenuated live vaccine includes Monovalent Vaccine and Combination Vaccine, and the revenue proportion of Monovalent Vaccine in 2016 was about 94.4%. Geographically, global Varicella Attenuated Live Vaccine market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer.

The top players including
Company Name
Company Type
Company Profile
Employees or Revenue
Products and Services
Established Date
Market Position or History
Contact Information

On the basis of product, we research the production, revenue, price, market share and growth rate, primarily split into
Monovalent Vaccine
Combination Vaccine

For the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Varicella Attenuated Live Vaccine for each application, including
Kids Injection
Adults Injection

Production, consumption, revenue, market share and growth rate are the key targets for Varicella Attenuated Live Vaccine from 2014 to 2026 (forecast) in these regions
Southeast Asia
South America

If you have any special requirements, please let us know and we will offer you the report as you want.

Please fill in the form below to Request for Customized Report
Your personal details are safe and secured with us. Privacy Policy

To request sample copy of this report, please complete the form below verified and secure

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report. This also includes a 30 minute free analyst discussion post report purchase.

Your personal details are safe and secured with us. Privacy Policy

    What Information does this report contain?

Purchase Options

Offers & Discounts

  • Chapter purchase
  • Historical market data
  • Country level data breakdown
  • Free customization*
  • Discounts for first time
  • Special pricing for
              non-business entities


  • We offer 20% free customization on every purchase.

Get in touch!

  +91 810 895 3541